Compare GMEX & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GMEX | ENSC |
|---|---|---|
| Founded | 2005 | 2003 |
| Country | Australia | United States |
| Employees | 16 | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7M | 1.7M |
| IPO Year | 2023 | N/A |
| Metric | GMEX | ENSC |
|---|---|---|
| Price | $0.79 | $0.25 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.8M | 887.9K |
| Earning Date | 04-17-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $55.01 |
| Revenue Next Year | N/A | $1,033.97 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.24 | $0.23 |
| 52 Week High | $2.50 | $2.75 |
| Indicator | GMEX | ENSC |
|---|---|---|
| Relative Strength Index (RSI) | 34.77 | 37.26 |
| Support Level | $0.35 | $0.23 |
| Resistance Level | $1.25 | $0.32 |
| Average True Range (ATR) | 0.27 | 0.03 |
| MACD | -0.11 | 0.00 |
| Stochastic Oscillator | 3.96 | 23.00 |
GMEX Robotics Corp is engaged in the design and deployment of AI-powered robotics and intelligent consumer technologies. The group operates in three business areas: Consumer and Commercial Robotics: Developing intuitive and interactive robots designed to assist with daily tasks, provide smart home integration, and offer new levels of convenience and connectivity to boost productivity; AI-Driven Hardware: Embedding artificial intelligence into physical products to create self-learning and adaptive user experiences; and Innovation & Ecosystem: Building a robust ecosystem of robotic products that communicate and evolve, powered by proprietary AI algorithms.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.